Protocol Title: Testing Decision Aids to Improve Prostate Cancer Decisions for Minority Men

Target Population: Adult and Senior Males, ages 18 and older with Stage I-III Prostate Cancer

Summary: This randomized phase III trial studies how well decision aids work in patients with newly diagnosed prostate cancer. Decision aids may improve patients’ knowledge of their condition and options for treatments, and may also help with talking with their doctor.

Key Inclusion Criteria:
- Patients must have prostate biopsy within 4 Months prior to registration showing newly diagnosed Prostate Cancer, Stage T1-3N0M0.
  - Note: In addition, patient must have a Gleason Score of 6-10.
- Prostate-Specific Antigen (PSA) < 50 ng/mL.
- Patients who have had a history of non-cutaneous malignancy in the previous 5 Years are NOT eligible.
  - Exception: Patients with history of non-melanoma skin cancer are eligible.
- Scheduled Prostate Cancer consultation to be the first consultation after diagnosis.
  - Note: Not a second-opinion or a consultation following previous discussions of treatment options.
- Patients may not be concurrently enrolled to another clinical trial for the treatment of cancer.
  - Co-enrollment to biospecimen studies is allowed.
- Patients must be able to read and comprehend English.
  - Non-English-speaking patients may participate so long as an interpreter (e.g., family member, clinic staff, etc.) is present for consent, for the decision aid administration, and gathering of baseline and follow-up measures.

Contacts:
Principal Investigator: Daniel Canter, MD
Research Nurses (RN): Dana Feist (dana.feist@ochsner.org, ext. 26330)

For additional information: https://clinicaltrials.gov/ct2/show/NCT03103321